V

Vericel Corp

D
VCEL
USD
1.985
(4.1311%)
Market Closed
14,906.00
Volume
0.19
EPS
-
Div Yield
5,003.50
P/E
2,453,224,806.13
Market Cap
Today
11.7601%
1 Week
13.535%
1 Month
21.858%
6 Months
0.877%
12 Months
36.932%
Year To Date
40.429%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALGN
-2.53
(-1.1249%)
USD
EW
EW
0.09
(0.1369%)
USD
ISRG
ISRG
9.03
(1.752%)
USD
TMO
TMO
-3.64
(-0.6504%)
USD
A
ABMD
(%)
USD
B
BAX
-0.07
(-0.1938%)
USD
BSX
BSX
0.45
(0.5205%)
USD
M
MTD
13.61
(0.9721%)
USD
RMD
RMD
3.02
(1.23%)
USD
S
STE
-11.81
(-5.1953%)
USD

Title:
Vericel Corp

Sector:
Healthcare
Industry:
Biotechnology
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Do you need help or have a question?
Contact Us